Yungjin Pharm. Co., Ltd.
Records under this name other than the patents Yungjin Pharm. Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 10 of 10 · Back to Yungjin Pharm. Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,969,653 | Extracellular Vesicles Derived from Gram-Positive Bacteria, and Use Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,927,085 | 1,2-naphthoquinone based derivative and method of preparing the same Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,066,922 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases Term ended Term ended Feb 15, 2026 · USPTO record | Term ended | Term ended Feb 15, 2026 | USPTO record |
| US 9,273,359 | Extracellular vesicles derived from Gram-positive bacteria, and use thereof Formerly held Lapsed on the fee record Ended Mar 1, 2024 · USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | USPTO record |
| US 9,180,101 | Pharmaceutical composition simultaneously having rapid-acting property and long-acting property Lapsed on the fee record Ended Nov 10, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 10, 2023 | USPTO record |
| US 8,029,832 | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity Lapsed on the fee record Ended Oct 4, 2023 · USPTO record | Lapsed on the fee record | Ended Oct 4, 2023 | USPTO record |
| US 8,466,141 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases Lapsed on the fee record Ended Jun 18, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 18, 2021 | USPTO record |
| US 8,404,869 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome Lapsed on the fee record Ended Mar 26, 2021 · USPTO record | Lapsed on the fee record | Ended Mar 26, 2021 | USPTO record |
| US 7,375,243 | Method for preparation of amino acid chelate Lapsed on the fee record Ended May 20, 2020 · USPTO record | Lapsed on the fee record | Ended May 20, 2020 | USPTO record |
| US 7,901,716 | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng Lapsed on the fee record Ended Mar 8, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 8, 2019 | USPTO record |